Rosen EM, Fan S, Goldberg ID 2001 BRCA1 and prostate cancer. Cancer Invest 19:396 - 412Rosen,E.M., Fan,S. and Goldberg,I.D. (2001) BRCA1 and prostate cancer. Cancer Invest., 19, 396EE412.Rosen EM, Fan S, Goldberg ID (2001) BRCA1 and prostate cancer. Cancer Invest 19: 396...
6.Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor Suppressor BRCA1 is Expressed in Prostate Cancer and Control IGF1-R Gene Transcription in an Androgen Receptor-Dependent Manner. Clin Cancer Res (2009) 15:1558–65. doi: 10.1158/1078-...
[3]Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79(8):880-895. doi:10.1002/pros.23795 [4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Ge...
[2]Olmos D, Lorente D, Alameda D, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. J Clin Oncol. 2023;41(supp...
B. A., Sapino, A., Cinieri, S., & Italian Scientific Societies (2022). Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies...
BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that es
[3]Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79(8):880-895. doi:10.1002/pros.23795 [4]Hu C, Hart SN, Polley EC, et al. Association Between Inherited Ge...
[2]Olmos D, Lorente D, Alameda D, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. J Clin Oncol. 2023;41(supp...
[2]Olmos D, Lorente D, Alameda D, et al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. J Clin Oncol. 2023;41(supp...
Prospective cohort study Prostate cancer 1. Introduction Deleterious mutations in the tumour suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer [1], [2], and have been implicated in the genetic susceptibility to prostate cancer (PCa). Retrospective studies...